SYNERGISTIC DNA-DAMAGING EFFECT IN MULTIPLE MYELOMA WITH THE COMBINATION OF ZALYPSIS, BORTEZOMIB AND DEXAMETHASONE

Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone

Despite new advances in multiple myeloma treatment and the consequent improvement in overall survival, most patients relapse or become refractory to treatment.This suggests that new molecules and combinations that may further inhibit important survival pathways for these tumor cells are needed.In this context, zalypsis is a novel compound, derived

read more